Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD) today and set a price target of $14. The company’s shares opened today at $6.36.
Olson noted:
“TXMD provided a business update including initial results for the Imvexxy launch. Imvexxy, the lowest dose estrogen product available for VVA, was approved by the FDA in May with commercial launch of the 10mcg dose on 4mcg dose expected in Sept. We’re impressed by early uptake of Imvexxy and encouraged by the potential for TX-001HR to treat menopausal symptoms with an Oct. 28 PDUFA and Annovera contraceptive ring launch in 2019. We believe early FDA approval of Annovera bolsters an already leading portfolio of differentiated women’s health products. Annovera is a one-year vaginal hormonal system for contraception. We believe this innovative portfolio of women’s health products is underappreciated and reiterate our Outperform rating for TXMD.”
According to TipRanks.com, Olson is a 2-star analyst with an average return of 0.4% and a 45.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on TherapeuticsMD is a Strong Buy with an average price target of $18, representing a 183.0% upside. In a report issued on August 23, Stifel Nicolaus also maintained a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 2.71M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
